Is glaucoma increasing road traffic accident rates?
by Gary Finnegan – World Health Matters (Japan) – Researchers in Japan have called for mandatory visual field testing for drivers in light of evidence showing glaucoma may… read more.
by Gary Finnegan – World Health Matters (Japan) – Researchers in Japan have called for mandatory visual field testing for drivers in light of evidence showing glaucoma may… read more.
by Gary Finnegan – World Health Matters (Germany) – Millions of people in Europe, the US and elsewhere use tanning beds every year ignoring the risk of skin… read more.
by Bruce Sylvester – Researchers report that respiratory symptoms vary significantly in different stages of the menstrual cycle, and that there are more symptoms during the mid-luteal to… read more.
by Bruce Sylvester – Patients with diabetes and multi-vessel coronary artery disease who undergo bypass surgery live longer, and they are less likely to have complications than those… read more.
by Bruce Sylvester – Findings from a study presented in November at the American Heart Association’s Scientific Sessions 2012 suggest that subjects with three to four aging signs,… read more.
by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
by Marybeth Burke – Crizotinib demonstrated significant anti-tumour activity in patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangements,
by Marybeth Burke – Women treated for childhood cancer with chest radiation therapy have a high risk of developing breast cancer at a young age, comparable to that… read more.
by Marybeth Burke – Regorafenib significantly improved progression-free survival (PFS) and disease control rate (DCR) in patients with advanced gastrointestinal stromal tumours (GIST) that progress due to resistance… read more.
by Marybeth Burke – The investigational agent trastuzumab emtansine (T-DM1) demonstrated improved efficacy over capecitibine plus lapatinib and improved progression-free survival (PFS) in women with HER2-positive locally advanced… read more.
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.